Semaglutide SOUL Trial Confirms Cardiovascular Benefits in Diabetic Kidney Disease
The SOUL cardiovascular outcomes trial confirms semaglutide reduces major adverse cardiac events in patients with type 2 diabetes and chronic kidney disease.
Novo Nordisk has announced positive topline results from the SOUL cardiovascular outcomes trial, demonstrating that once-weekly injectable semaglutide significantly reduces major adverse cardiovascular events in patients with type 2 diabetes and chronic kidney disease. The findings extend the known cardioprotective benefits of GLP-1 receptor agonists to a high-risk population with substantial unmet medical need.
What We Know
The SOUL (Semaglutide cardiOvascular oUtcomes triaL) trial enrolled approximately 9,600 participants with type 2 diabetes and stage 3-4 chronic kidney disease, a population at markedly elevated risk for cardiovascular morbidity and mortality. Participants were randomized to receive semaglutide 1.0 mg weekly or placebo in addition to standard of care [soul-trial-results].
The primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke occurred in significantly fewer patients receiving semaglutide compared to placebo. The hazard ratio of 0.82 represents an 18% relative risk reduction, achieving the prespecified threshold for superiority.
Secondary analyses showed consistent benefits across individual components of the composite endpoint, with point estimates favoring semaglutide for each. The treatment effect was maintained across subgroups defined by baseline kidney function, suggesting benefit even in patients with more advanced kidney disease [nejm-soul].
Clinical Context
Patients with both diabetes and chronic kidney disease face compounding cardiovascular risk. Traditional risk reduction strategies including blood pressure control, lipid management, and glycemic optimization provide benefit but leave substantial residual risk. SGLT2 inhibitors have emerged as a cornerstone therapy in this population, and the SOUL results position GLP-1 agonists as an additional proven intervention.
The trial design specifically examined cardiovascular outcomes rather than kidney outcomes, complementing the earlier FLOW trial that demonstrated semaglutide’s renal protective effects. Together, these trials provide comprehensive evidence for semaglutide’s cardiorenal benefits [novo-announcement].
What It Means
For clinicians managing patients with type 2 diabetes and chronic kidney disease, SOUL provides definitive evidence supporting semaglutide use for cardiovascular risk reduction. Current guidelines already recommend GLP-1 agonists in patients with established cardiovascular disease; these results may prompt expanded recommendations specifically for the CKD population.
The practical implications for prescribing are significant. Many patients with diabetic kidney disease have been hesitant to use GLP-1 agonists due to gastrointestinal side effects or uncertainty about benefit in their specific situation. Clear trial evidence may encourage broader adoption.
From a healthcare system perspective, reducing cardiovascular events in this high-cost population could generate substantial downstream savings despite the medication’s cost. Hospitalizations for heart attacks and strokes, along with subsequent cardiac procedures and rehabilitation, represent major expenditures that effective prevention can reduce.
What’s Next
Full trial results including detailed subgroup analyses, safety data, and secondary endpoints will be presented at a major cardiology conference in early 2026 and simultaneously published in a peer-reviewed journal. These data will clarify which patient subsets derive the greatest benefit.
Regulatory submissions are anticipated to update semaglutide’s label with the SOUL results, formally documenting cardiovascular benefit in the CKD population. Both the FDA and EMA typically review such supplemental applications expeditiously given the strength of outcomes trial evidence.
Ongoing research continues to explore optimal combination strategies. Whether adding a GLP-1 agonist to an SGLT2 inhibitor provides additive cardiovascular benefit beyond either agent alone remains an active area of investigation, with dedicated trials underway.
The results also have implications for the development of newer GLP-1 receptor agonists and multi-agonist combinations. Cardiovascular outcomes benefits appear to be a class effect, supporting continued investment in this therapeutic mechanism.
This information is provided for educational purposes only and does not constitute medical advice.
Sources & Citations
- 1
- 2
- 3
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.